Literature DB >> 27252510

Innovation in hematology. Perspectives: CML 2016.

Rüdiger Hehlmann1.   

Abstract

Mesh:

Year:  2016        PMID: 27252510      PMCID: PMC5013944          DOI: 10.3324/haematol.2016.142877

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

Authors:  Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

2.  CML--Where do we stand in 2015?

Authors:  Rüdiger Hehlmann
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

3.  Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.

Authors:  Noortje Thielen; Otto Visser; Gert Ossenkoppele; Jeroen Janssen
Journal:  Eur J Haematol       Date:  2015-11-30       Impact factor: 2.997

Review 4.  Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.

Authors:  Lucien Noens; Marja Hensen; Izabela Kucmin-Bemelmans; Christina Lofgren; Isabelle Gilloteau; Bernard Vrijens
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

5.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Authors:  Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Susanne Schnittger; Claudia Haferlach; Stefan W Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C Müller
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

6.  The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Authors:  V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann
Journal:  Leukemia       Date:  2015-03-18       Impact factor: 11.528

7.  Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Authors:  Susanne Saussele; Marie-Paloma Krauss; Rüdiger Hehlmann; Michael Lauseker; Ulrike Proetel; Lida Kalmanti; Benjamin Hanfstein; Alice Fabarius; Doris Kraemer; Wolfgang E Berdel; Martin Bentz; Peter Staib; Maike de Wit; Martin Wernli; Florian Zettl; Holger F Hebart; Markus Hahn; Jochen Heymanns; Ingo Schmidt-Wolf; Norbert Schmitz; Michael J Eckart; Winfried Gassmann; Andrea Bartholomäus; Antonio Pezzutto; Elisabeth Oppliger Leibundgut; Dominik Heim; Stefan W Krause; Andreas Burchert; Wolf-Karsten Hofmann; Joerg Hasford; Andreas Hochhaus; Markus Pfirrmann; Martin C Müller
Journal:  Blood       Date:  2015-04-27       Impact factor: 22.113

8.  Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Authors:  Martin Höglund; Fredrik Sandin; Karin Hellström; Mats Björeman; Magnus Björkholm; Mats Brune; Arta Dreimane; Marja Ekblom; Sören Lehmann; Per Ljungman; Claes Malm; Berit Markevärn; Kristina Myhr-Eriksson; Lotta Ohm; Ulla Olsson-Strömberg; Anders Själander; Hans Wadenvik; Bengt Simonsson; Leif Stenke; Johan Richter
Journal:  Blood       Date:  2013-07-10       Impact factor: 22.113

Review 9.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Authors:  N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528

10.  Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Authors:  A Gratwohl; M Pfirrmann; A Zander; N Kröger; D Beelen; J Novotny; C Nerl; C Scheid; K Spiekermann; J Mayer; H G Sayer; C Falge; D Bunjes; H Döhner; A Ganser; I Schmidt-Wolf; R Schwerdtfeger; H Baurmann; R Kuse; N Schmitz; A Wehmeier; J Th Fischer; A D Ho; M Wilhelm; M-E Goebeler; H W Lindemann; M Bormann; B Hertenstein; G Schlimok; G M Baerlocher; C Aul; M Pfreundschuh; M Fabian; P Staib; M Edinger; M Schatz; A Fauser; R Arnold; T Kindler; G Wulf; A Rosselet; A Hellmann; E Schäfer; O Prümmer; M Schenk; J Hasford; H Heimpel; D K Hossfeld; H-J Kolb; G Büsche; C Haferlach; S Schnittger; M C Müller; A Reiter; U Berger; S Saußele; A Hochhaus; R Hehlmann
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

View more
  5 in total

1.  Research in the heart of hematology: chronic myeloid leukemia 2017.

Authors:  Rüdiger Hehlmann
Journal:  Haematologica       Date:  2017-03       Impact factor: 9.941

2.  Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.

Authors:  Laura Damele; Elisa Montaldo; Lorenzo Moretta; Chiara Vitale; Maria Cristina Mingari
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

3.  Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia.

Authors:  Leo Reap; Lyle Goldman
Journal:  Leuk Res Rep       Date:  2020-10-06

Review 4.  A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.

Authors:  Nataliia Lopina; Iryna Dmytrenko; Dmytro Hamov; Dmytro Lopin; Iryna Dyagil
Journal:  Cureus       Date:  2022-06-08

Review 5.  Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?

Authors:  Laura Damele; Selene Ottonello; Maria Cristina Mingari; Gabriella Pietra; Chiara Vitale
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.